Hepatitis B virus prevalence and risk factors in hard-to-reach Turkish population living in Belgium: A protocol for screening

Abstract

Background: Hepatitis B virus (HBV) infection is an important public health problem in the Turkish population, that is, one of the largest migrant populations in Europe. With the introduction of cost-effective antiviral treatments in the past decade, there is a need to identify HBV-infected patients who may benefit from treatment. This study describes the design of a study to assess the HBV prevalence in the Turkish population living in Belgium. Additionally, we will determine the risk factors of HBV infection and the uptake of screening, vaccination, and antiviral treatment in this hard-to-reach Turkish population.

Methods: A longitudinal, epidemiological study will be conducted in the region Middle Limburg Belgium, where the Turkish adult population, 18 years of age and older, will be screened for hepatitis B surface antigen (HBsAg), antibodies against HBsAg (anti-HBs), and antibodies against hepatitis B core antigen (anti-HBc). Educational meetings concerning viral hepatitis B will be organized and there will be 3 ways to be screened for HBV: immediately after the educational meetings, at the Outpatient Hepatology Department of Ziekenhuis Oost-Limburg, and at home visits. Subsequently, participants will be asked to fill in a questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection (e.g., sharing toothbrushes, HBV-infected family member), and HBV vaccination status. Six months after screening, HBsAg-positive patients will be assessed whether they are under follow-up at the general practitioner or hepatologist. We will also gather information regarding the uptake of vaccination in nonimmunized subjects.

Discussion: This study will provide information about the HBV prevalence and distribution of the stages of liver disease in the Turkish population in Belgium. By determining the risk factors for HBV infection, subgroups with an increased prevalence of HBV infection can be identified.

Clinical trial number: This clinical trial is registered at clinicaltrials.gov (NCT03396458).

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1

Flowchart of the study design. HBV = hepatitis B virus, HBsAg = hepatitis B surface antigen, anti-HBs = antibodies against hepatitis B surface antigen, anti-HBc = antibodies against hepatitis B core antigen, ZOL = Ziekenhuis Oost-Limburg.

Figure 2

Map of Turkey according to the geographical regions. Map of Turkey according to regions: (A) Marmara, (B) Aegean, (C) Mediterranean, (D) Central Anatolia, (E) Black Sea, (F) Eastern Anatolia, and (G) Southeastern Anatolia.